X0306 4 2014-02-11 0 0000885590 Valeant Pharmaceuticals International, Inc. VRX 0001564233 Weldon Ryan 2150 ST. ELZEAR BLVD. WEST LAVAL A8 H7L 4A8 QUEBEC, CANADA 0 1 0 0 EVP, Company Group Chairman Common Stock, no par value 2014-02-11 4 M 0 11000 0 A 103823 D Common Stock, no par value 2014-02-11 4 F 0 5707 0 D 98116 D Restricted Share Units 2014-02-11 4 M 0 11000 0 D Common Stock 11000 11000 D This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $62.62 starting on January 28, 2013 and the average stock price for the 20 trading days starting on each measurement dates: 25% on October 28, 2015, 50% on January 28, 2016 and 25% on April 28, 2016. Unit vesting is contingent on TSR performance between 10% and 30% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. The PSU award may still payout two times grant value. This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Performance Share Units. by: Nicholas Zanoni for Ryan Weldon 2014-02-12